BioAmber Inc (fka BIOAQ)

[Penman1]

In the Visolis Exhibit R-3A it state the LCY generates a "free cash flow" of XXXXXXXX.

Here are the "free cash" figures for years 2013-2017:

2013 --- 2014 ---- 2015 --- 2016 --- 2017
1.19B --(2.92B) -- 4.92B --3.96B --3.03B

SEE: https://www.marketwatch.com/investing/stock/1704/financials/cash-flow

Now the purchase price listed, but blacked out, on the same page is enough space for a dollar sign, to wit, $, and 9 figures, excluding commas, or:

$000,000,000 suggesting a purchase price at least > $100,000,000.

Let this at least be our speculative starting point, or base price platform, if you will. LCY/Visolis knows what the facility is worth in terms of fair market value; they know what the outstanding debt is; and, in this document, they made a point of focusing on, in their purchase, of all intellectual property, patents, etc., so lets add at least $70M to the based platform, for they know the BIOA process can generate $1.2B in revenue per year when fully operational.

Therefore, we ought to be able to conclude that a speculative base purchasing prices would be AT LEAST > $170,000,000.
-